Mary R. Galinski, PhD


Medicine, Infectious Diseases


Emory Vaccine Center

ARTDTP Research Discipline

Malaria is the most devastating parasitic disease reported in about 100 countries. This mosquito-borne disease is responsible for several hundred million clinical cases and up to one million fatalities annually, and about 40 percent of the world's population lives in areas where the disease is transmitted. Drug resistance is a major worldwide problem. Developing effective malaria vaccines, rapid diagnostic tests and new anti-malarial drugs are top global research priorities. The Emory Vaccine Center’s malaria research team, led by Galinski, is among a few worldwide with the ability to study in depth the most predominant human malaria parasite species (P. falciparum and P. vivax), as well as several non-human primate and rodent malaria parasites. Studies with multiple experimental model system are critical for the development of this team’s research. Importantly, recent investigations on the blood-stage proteomes of P. vivax and related nonhuman primate malaria parasites in conjunction with molecular and cell biological studies are helping to reveal novel targets for possible intervention for P. vivax. Transgenic technologies are also being utilized to investigate the elusive hypnozoite form of this species in the liver. The nonhuman primate models and systems biology approaches are enabling a broad understanding of the parasite and its infection, with basic discovery, the testing of interventions, and improved understanding of the biology, immune evasion strategies, and pathogenesis of the disease. Galinski and her team recently formed Emory’s Malaria-Host Pathogen Interaction Center to study malaria systems biology with the award of an NIAID contract that supports many local and international collaborators.

ARTDTP Faculty Collaborators

Tracey Lamb, PhD

Dennis C. Liotta, PhD

David S. Weiss, PhD